<DOC>
	<DOCNO>NCT02370615</DOCNO>
	<brief_summary>The purpose study evaluate effect repeated-dose administration itraconazole pharmacokinetics TAK-272 , well effect repeated-dose administration TAK-272 pharmacokinetics digoxin midazolam healthy Japanese adult male .</brief_summary>
	<brief_title>Drug-Drug Interaction Study Between TAK-272 Itraconazole , Digoxin Midazolam</brief_title>
	<detailed_description>In Cohort 1 , effect repeated-dose administration itraconazole pharmacokinetics TAK-272 evaluate compare participant receive TAK-272 alone receive TAK-272 combination itraconazole . In Cohort 2 , effect repeated-dose administration TAK-272 pharmacokinetics digoxin midazolam evaluate compare participant receive digoxin midazolam alone receive either drug combination TAK-272 .</detailed_description>
	<mesh_term>Itraconazole</mesh_term>
	<mesh_term>Hydroxyitraconazole</mesh_term>
	<mesh_term>Digoxin</mesh_term>
	<mesh_term>Midazolam</mesh_term>
	<criteria>1 . Is capable understand comply protocol requirement . 2. Who sign date inform consent form initiation study procedure . 3 . Healthy Japanese adult male volunteer . 4 . Is 20 35 year age time inform consent 5 . Weighs 50 kilogram ( kg ) body mass index ( BMI ) 18.5 less 25.0 kilogram per square meter ( kg/m^2 ) screen test . 6 . Male participant nonsterilized sexually active female partner childbearing potential agree use adequate contraception signing inform consent throughout duration study 12 week completion study . 1. Who administer investigational product within 16 week ( 112 day ) prior initial drug administration . 2. Who receive TAK272 previous . 3 . Employees study site , family member , dependency relationship employee study site involve conduct study ( example , spouse , parent , child , brother sister ) , might coerce consent participate study . 4. Who poorly control , clinically significant abnormality nervous system , cardiovascular system , lung , liver , kidney , metabolism , gastrointestinal system , urinary system , endocrinological system organs system , may possibly affect study participation study result . 5. Who history serious hepatic disease . 6. Who atrioventricular block sinoatrial block . 7 . Has digitalis intoxication . 8 . Has acute narrowangle glaucoma . 9 . Has myasthenia gravis . 10 . Has hypersensitivity TAK272 renin inhibitor . 11 . Has hypersensitivity itraconazole , digoxin , digitalis preparation , midazolam . 12 . Has allergy cherry . 13 . Has positive urine test drug abuse screen . 14 . Has history drug abuse ( defined illegal drug use ) alcohol addiction within 1 year prior screen visit , willing give alcohol drug study period . 15. Who need use prohibit concomitant drug , vitamin , food list table prohibit concomitant drug food , participant use period prohibit concomitant use . 16 . Male participant plan donate sperm study period 12 week end study . 17. Who currently cardiovascular , central nervous , hepatic , hematopoietic disease , renal insufficiency , metabolic endocrinological disorder , serious allergy , asthma , hypoxemia , hypertension , convulsion , allergic rash . 18 . Has disease history , examination finding , clinical test finding relate safety reasonably suggest disease TAK 272 relate renin inhibitor class , itraconazole , digoxin , midazolam contraindicate disease may affect study conduct ( include , example , peptic ulcer disease , convulsive disorder , arrhythmia ) . 19. Who currently recently ( within past 6 month ) gastrointestinal disease may affect drug absorption ( malabsorption , esophageal reflux , peptic ulcer disease , erosive esophagitis , frequent [ least week ] heartburn , surgical intervension [ e.g. , cholecystectomy ] ) . 20 . Has past history cancer . 21. Who positive follow screening : hepatitis B virus surface antigen ( HBs ) , antibody hepatitis C virus ( HCV ) , human immunodeficiency virus ( HIV ) antigen , antiHIV antibody , serological test syphilis . 22 . The participant difficulty blood collect peripheral vein . 23. Who donate 200 milliliter ( mL ) whole blood within 4 week ( 28 day ) 400 mL whole blood within 12 week ( 84 day ) start study drug administration . 24. Who donate total 800 mL whole blood within 52 week ( 364 day ) day start study drug administration . 25. Who donate blood component within 2 week ( 14 day ) start study drug administration . 26. Who show clinically significant abnormality electrocardiogram screen study drug administration . 27. Who show laboratory test abnormality suggestive clinically significant primary disease show abnormal value follow parameter screen study drug administration : alanine aminotransferase ( ALT ) and/or aspartate aminotransferase ( AST ) exceed 1.5 time upper limit normal range . 28. Who unlikely comply study protocol ineligible study reason , consider investigator sub investigator . 29. Who systolic blood pressure 80 millimeter mercury ( mmHg ) Screening , pretreatment examination , start study drug administration , suspect hypotension 2 follow symptom finding physical examination : dizziness postural , facial pallor , cold sweat .</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>